Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation, a company focused on developing treatments for chronic hepatitis B, is set to engage with investors at two major conferences in New York this May. Both events will feature fireside chats with the Arbutus management team, which will be available as live webcasts and archived replays on the company’s website. Arbutus’s current pipeline includes promising clinical trials for its RNAi therapeutic and an oral PD-L1 inhibitor.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
